Shades of grey: arguments for and against parallel trade in pharmaceuticals
Last month the European Court of Justice announced its judgment on Syfait v GlaxoSmithKline, the latest case concerning parallel trading (aka grey imports). One of the most pressing competition issues facing the pharmaceutical industry, this topic was discussed during the second Oxera Economics Council meeting that took place in Brussels on September 15th.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!